{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:34:37Z","timestamp":1789619677264,"version":"build-2803163510"},"reference-count":42,"publisher":"Walter de Gruyter GmbH","issue":"1","funder":[{"name":"Central Council for Research in Unani Medicine (CCRUM), Ministry of AYUSH, Government of India","award":["16314222002D"],"award-info":[{"award-number":["16314222002D"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jcim-2021-0057_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      Greco-Arab medicine is an ancient system of medicine with greater treasure on therapeutics of vitiligo. The trial Unani formulations have not been scientifically explored for their safety and efficacy, but have been repeatedly prescribed by the great Unani physicians in the management of\n                      <jats:italic>Bara\u1e63<\/jats:italic>\n                      (vitiligo). Hence, these interventions were selected for the trial.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2021-0057_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this randomized, controlled, open-label clinical trial, 82 participants with non-segmental vitiligo aged 18\u201340 years were block randomized to either receive Unani interventions or control for 16\u00a0weeks. Out of 82 participants, 42 were randomized to the Unani group and 40 were randomized to the control group. The primary outcome measure was change in vitiligo area scoring index (VASI), which was assessed on weeks 4, 8, 12 and 16. The secondary outcome measures included the patient\u2019s global assessment on VAS and investigator\u2019s global assessment based on photographic evaluation at baseline and after the treatment. Safety parameters included hemogram, LFTs, RFTs, CXR, ECG, urine, and stool examinations, which were evaluated at baseline and after the treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2021-0057_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The per-protocol analysis was done on 30 participants in each group and the response in Unani group was not inferior to those receiving control group. The mean\u00a0\u00b1\u00a0SD of vitiligo area scoring index (VASI) decreased from 4.09\u00a0\u00b1\u00a02.87 and 5.50\u00a0\u00b1\u00a05.73 at baseline to 3.13\u00a0\u00b1\u00a02.20 and 4.29\u00a0\u00b1\u00a04.95 at the end of the trial in both the Unani and control groups respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2021-0057_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The study inferred that both the interventions are equally effective and well-tolerated in patients with non-segmental vitiligo.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jcim-2021-0057","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T20:19:13Z","timestamp":1624479553000},"page":"250-257","source":"Crossref","is-referenced-by-count":7,"title":["A non-inferiority randomized controlled clinical trial comparing Unani formulations and PUVAsol in non-segmental vitiligo"],"prefix":"10.1515","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8933-3447","authenticated-orcid":false,"given":"Nazim","family":"Husain","sequence":"first","affiliation":[{"name":"Department of Moalajat , Luqman Unani Medical College Hospital & Research Center , Bijapur , Karnataka , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qamar","family":"Uddin","sequence":"additional","affiliation":[{"name":"National Research Institute of Unani Medicine for Skin Disorders , Hyderabad , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munawwar Husain","family":"Kazmi","sequence":"additional","affiliation":[{"name":"National Research Institute of Unani Medicine for Skin Disorders , Hyderabad , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd","family":"Khalid","sequence":"additional","affiliation":[{"name":"Department of Moalajat , Luqman Unani Medical College Hospital & Research Center , Bijapur , Karnataka , India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"2025121209012902091_j_jcim-2021-0057_ref_001","unstructured":"Christopher, G, Barker, J, Bleiker, T, Robert, C, Creamer, D. Acquired Pigmentary Disorders. Rook\u2019s Textb. Dermatology, 9th ed., vol. 3. Wiley-Blackwell; 2016:88.34\u20136 pp."},{"key":"2025121209012902091_j_jcim-2021-0057_ref_002","doi-asserted-by":"crossref","unstructured":"Ezzedine, K, Sheth, V, Rodrigues, M, Eleftheriadou, V, Harris, JE, Hamzavi, IH, et al.. Vitiligo is not a cosmetic disease. J Am Acad Dermatol 2015;73:883\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2015.07.039.","DOI":"10.1016\/j.jaad.2015.07.039"},{"key":"2025121209012902091_j_jcim-2021-0057_ref_003","doi-asserted-by":"crossref","unstructured":"Porter, J, Beuf, A, Nordlund, JJ, Lerner, AB. Personal responses of patients to vitiligo: the importance of the patient-physician interaction. Arch Dermatol 1978;114:1384\u20135. https:\/\/doi.org\/10.1001\/archderm.1978.01640210075025.","DOI":"10.1001\/archderm.1978.01640210075025"},{"key":"2025121209012902091_j_jcim-2021-0057_ref_004","doi-asserted-by":"crossref","unstructured":"Kr\u00fcger, C, Schallreuter, KU. A review of the worldwide prevalence of vitiligo in children\/adolescents and adults. Int J Dermatol 2012;51:1206\u201312. https:\/\/doi.org\/10.1111\/j.1365-4632.2011.05377.x.","DOI":"10.1111\/j.1365-4632.2011.05377.x"},{"key":"2025121209012902091_j_jcim-2021-0057_ref_005","doi-asserted-by":"crossref","unstructured":"Yaghoobi, R, Omidian, M, Bagherani, N. Vitiligo: a review of the published work. J Dermatol 2011;38:419\u201331. https:\/\/doi.org\/10.1111\/j.1346-8138.2010.01139.x.","DOI":"10.1111\/j.1346-8138.2010.01139.x"},{"key":"2025121209012902091_j_jcim-2021-0057_ref_006","doi-asserted-by":"crossref","unstructured":"Ta\u00efeb, A, Picardo, M. Clinical practice. Vitiligo. N Engl J Med 2009;360:160\u20139. https:\/\/doi.org\/10.1056\/nejmcp0804388.","DOI":"10.1056\/NEJMcp0804388"},{"key":"2025121209012902091_j_jcim-2021-0057_ref_007","doi-asserted-by":"crossref","unstructured":"Hann, SK, Lee, HJ. Segmental vitiligo: clinical findings in 208 patients. J Am Acad Dermatol 1996;35:671\u20134. https:\/\/doi.org\/10.1016\/s0190-9622(96)90718-5.","DOI":"10.1016\/S0190-9622(96)90718-5"},{"key":"2025121209012902091_j_jcim-2021-0057_ref_008","doi-asserted-by":"crossref","unstructured":"Schallreuter, KU, Bahadoran, P, Picardo, M, Slominski, A, Elassiuty, YE, Kemp, EH, et al.. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol 2008;17:139\u201340. https:\/\/doi.org\/10.1111\/j.1600-0625.2007.00666_1.x.","DOI":"10.1111\/j.1600-0625.2007.00666_1.x"},{"key":"2025121209012902091_j_jcim-2021-0057_ref_009","doi-asserted-by":"crossref","unstructured":"Spritz, RA. The genetics of generalized vitiligo and associated autoimmune diseases. Pigm Cell Res 2007;20:271\u20138. https:\/\/doi.org\/10.1111\/j.1600-0749.2007.00384.x.","DOI":"10.1111\/j.1600-0749.2007.00384.x"},{"key":"2025121209012902091_j_jcim-2021-0057_ref_010","unstructured":"R\u0101z\u012b ABM ibn, Z. Disease of the Skin (Ringworm, Leukoderma, Leprosy etc.) and Dyes of Hair and Hands. Kit\u0101b al-\u1e24\u0101w\u012b f\u2019il \u1e6cibb (Arabic version), vol. 23, Part-II, 1st ed., Hyderabad: Dairatul Marif, Osmania University (Osmania Oriental Publication Bureau); 1970:88\u2013119 pp."},{"key":"2025121209012902091_j_jcim-2021-0057_ref_011","unstructured":"\u1e6cabr\u012b, A, \u1e24asan A bin, M. Al-Mu\u2018\u0101lajat al-Buqr\u0101\u1e6diya, vol. II. New Delhi: Central Council For Research in Unani Medicine; 1997:199\u2013200 pp."},{"key":"2025121209012902091_j_jcim-2021-0057_ref_012","unstructured":"Ibn S\u012bn\u0101, A. Al-Q\u0101n\u016bn fi\u2019l \u1e6cibb, 1st ed. Lahore: Shaikh Muhammad Basheer and Sons, Urdu Bazar; n.d.:351\u20133 pp."},{"key":"2025121209012902091_j_jcim-2021-0057_ref_013","unstructured":"Jurj\u0101ni, AH. Dhakh\u012bra Khaw\u0101rizm Sh\u0101h\u012b. New Delhi: Idara Kitab-us-Shifa, 2075, Kucha Chelan, Darya Ganj; 2010:18\u201321 pp."},{"key":"2025121209012902091_j_jcim-2021-0057_ref_014","unstructured":"\u1e6cibb-i Akbar, AA. Deoband. Jama Masjid, Deoband: Faisal Publications; n.d.:731\u20132 pp."},{"key":"2025121209012902091_j_jcim-2021-0057_ref_015","unstructured":"G\u0101zr\u016bn\u012b S al-D. Al-Sad\u012bd\u012b (Arabic). Lucknow: Ma\u1e6dba Munshi Nawal Kishor. Lucknow, India, U.P.; n.d.:61\u20132 pp."},{"key":"2025121209012902091_j_jcim-2021-0057_ref_016","unstructured":"Standard Unani Medical Terminology. New Delhi: Central Council For Research in Unani Medicine; 2012:32 p."},{"key":"2025121209012902091_j_jcim-2021-0057_ref_017","unstructured":"R\u0101z\u012b ABM ibn, Z. Kit\u0101b al-Man\u1e63\u016br\u012b (Urdu Translation). New Delhi: Central Council For Research in Unani Medicine; 1991."},{"key":"2025121209012902091_j_jcim-2021-0057_ref_018","doi-asserted-by":"crossref","unstructured":"Whitton, ME, Pinart, M, Batchelor, J, Leonardi-Bee, J, Gonz\u00e1lez, U, Jiyad, Z, et al.. Interventions for vitiligo. Cochrane Database Syst Rev 2015;2015. https:\/\/doi.org\/10.1002\/14651858.CD003263.pub5.","DOI":"10.1002\/14651858.CD003263.pub5"},{"key":"2025121209012902091_j_jcim-2021-0057_ref_019","doi-asserted-by":"crossref","unstructured":"Shenoi, S, Prabhu, S. Photochemotherapy (PUVA) in psoriasis and vitiligo. Indian J Dermatol Venereol Leprol 2014;80:497\u2013504. https:\/\/doi.org\/10.4103\/0378-6323.144143.","DOI":"10.4103\/0378-6323.144143"},{"key":"2025121209012902091_j_jcim-2021-0057_ref_020","doi-asserted-by":"crossref","unstructured":"Allam, M, Riad, H. Concise review of recent studies in vitiligo. Qatar Med J 2013;2013:1\u201319. https:\/\/doi.org\/10.5339\/qmj.2013.10.","DOI":"10.5339\/qmj.2013.10"},{"key":"2025121209012902091_j_jcim-2021-0057_ref_021","unstructured":"The Unani Pharmacopoeia of India Part-I, vol. IV. New Delhi: Dept. of AYUSH, Ministry of Health & Family Welfare, Government of India; 2007."},{"key":"2025121209012902091_j_jcim-2021-0057_ref_022","unstructured":"National Formulary of Unani Medicine Part-II, vol. I. New Delhi: Dept. of AYUSH, Ministry of Health & Family Welfare, Government of India; 2007."},{"key":"2025121209012902091_j_jcim-2021-0057_ref_023","unstructured":"Husain, N, Qamaruddin, Kazmi, MH. Clinical studies on the treatment of Bara\u1e63 (vitiligo) in Unani system of medicine\u2014a systematic review. Eur J Biomed Pharmaceut Sci 2018;5:1088\u201394."},{"key":"2025121209012902091_j_jcim-2021-0057_ref_024","unstructured":"Kab\u012bruddin, H. Makhzan al-Mufrad\u0101t (Khw\u0101\u1e63 al-Advia). New Delhi: Ejaz Publicating House; 2007:107 p."},{"key":"2025121209012902091_j_jcim-2021-0057_ref_025","unstructured":"Hak\u012bm K. Al-Qar\u0101b\u0101d\u012bn. Taba\u02bb S\u0101ni. New Delhi: Central Council For Research in Unani Medicine; 2006:231 p."},{"key":"2025121209012902091_j_jcim-2021-0057_ref_026","doi-asserted-by":"crossref","unstructured":"Ravishankar, V, Rathod, SP, Saikia, S, Chaudhary, RG, Solanki, RB. A study of comparison of PUVASOL and NBUVB in patients with vitiligo. Pigment Int 2018;5:96.","DOI":"10.4103\/Pigmentinternational.Pigmentinternational_39_17"},{"key":"2025121209012902091_j_jcim-2021-0057_ref_027","doi-asserted-by":"crossref","unstructured":"Naveen, N, Hanumanthappa, H. Clinico-epidemiological study of vitiligo and its correlation with thyroid function. J Evid Based Med Healthc 2015;2:6227\u201334. https:\/\/doi.org\/10.18410\/jebmh\/2015\/858.","DOI":"10.18410\/jebmh\/2015\/858"},{"key":"2025121209012902091_j_jcim-2021-0057_ref_028","doi-asserted-by":"crossref","unstructured":"Krupa Shankar, D, Madala, R, Shashikala, K. Clinical patterns of vitiligo and its associated co morbidities: a prospective controlled cross-sectional study in South India. Indian Dermatol Online J 2012;3:114. https:\/\/doi.org\/10.4103\/2229-5178.96705.","DOI":"10.4103\/2229-5178.96705"},{"key":"2025121209012902091_j_jcim-2021-0057_ref_029","unstructured":"Martis, J, Bhat, R, Nandakishore, B, Shetty, JN. A clinical study of vitiligo. Indian J Dermatol Venereol Leprol 2002;68:92\u20133."},{"key":"2025121209012902091_j_jcim-2021-0057_ref_030","doi-asserted-by":"crossref","unstructured":"Lerner, AB, Nordlund, JJ. Vitiligo: what is it? Is it important? JAMA J Am Med Assoc 1978;239:1183\u20137. https:\/\/doi.org\/10.1001\/jama.1978.03280390079031.","DOI":"10.1001\/jama.1978.03280390079031"},{"key":"2025121209012902091_j_jcim-2021-0057_ref_031","doi-asserted-by":"crossref","unstructured":"Sehgal, VN, Srivastava, G. Vitiligo: compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol 2007;73:149\u201356. https:\/\/doi.org\/10.4103\/0378-6323.32708.","DOI":"10.4103\/0378-6323.32708"},{"key":"2025121209012902091_j_jcim-2021-0057_ref_032","unstructured":"Ali, D, Mannan, A, Misbahuddin, S. Bars aur uskey ilaj mein safoof bars ki ifadiat ka jaiza. Aligarh Muslim University; 2015."},{"key":"2025121209012902091_j_jcim-2021-0057_ref_033","doi-asserted-by":"crossref","unstructured":"Gopal, KVT, Rama Rao, GR, Kumar, YHK, Appa Rao, MV, Vasudev, P, Srikant. Vitiligo: a part of a systemic autoimmune process. Indian J Dermatol Venereol Leprol 2007;73:162\u20135. https:\/\/doi.org\/10.4103\/0378-6323.32710.","DOI":"10.4103\/0378-6323.32710"},{"key":"2025121209012902091_j_jcim-2021-0057_ref_034","unstructured":"Dave, S, Thappa, D, Dsouza, M. Clinical predictors of outcome in vitiligo. Indian J Dermatol Venereol Leprol 2002;68:323\u20135."},{"key":"2025121209012902091_j_jcim-2021-0057_ref_035","unstructured":"Behl, PN, Kotia, A, Sawal, P. Vitiligo: age-group related trigger factors and morphological variants. Indian J Dermatol Venereol Leprol 1994;60:275\u20139."},{"key":"2025121209012902091_j_jcim-2021-0057_ref_036","doi-asserted-by":"crossref","unstructured":"Shajil, E, Agrawal, D, Vagadia, K, Marfatia, Y, Begum, R. Vitiligo: clinical profiles in Vadodara, Gujarat. Indian J Dermatol 2006;51:100\u20134.","DOI":"10.4103\/0019-5154.26928"},{"key":"2025121209012902091_j_jcim-2021-0057_ref_037","doi-asserted-by":"crossref","unstructured":"Sultan, T, Ali, SA. Psoralea corylifolia extracts stimulate cholinergic-like psoralen receptors of tadpole-tail melanophores, leading to skin darkening. J Recept Signal Transduct 2011;31:39\u201344. https:\/\/doi.org\/10.3109\/10799893.2010.508164.","DOI":"10.3109\/10799893.2010.508164"},{"key":"2025121209012902091_j_jcim-2021-0057_ref_038","doi-asserted-by":"crossref","unstructured":"Yin, L, Pang, G, Niu, C, Habasi, M, Dou, J, Aisa, HA. A novel psoralen derivative-MPFC enhances melanogenesis via activation of p38 MAPK and PKA signaling pathways in B16 cells. Int J Mol Med 2018;41:3727\u201335. https:\/\/doi.org\/10.3892\/ijmm.2018.3529.","DOI":"10.3892\/ijmm.2018.3529"},{"key":"2025121209012902091_j_jcim-2021-0057_ref_039","doi-asserted-by":"crossref","unstructured":"Kumar, VS, Navaratnam, V. Neem (Azadirachta indica): prehistory to contemporary medicinal uses to humankind. Asian Pac J Trop Biomed 2013;3:505\u201314. https:\/\/doi.org\/10.1016\/s2221-1691(13)60105-7.","DOI":"10.1016\/S2221-1691(13)60105-7"},{"key":"2025121209012902091_j_jcim-2021-0057_ref_040","doi-asserted-by":"crossref","unstructured":"Jadhav, PB. Chemical leucoderma of oral and labial mucosal surfaces from neem [Azadirachta indica]. A case series. Indian Dermatol Online J 2020;11:433\u20135. https:\/\/doi.org\/10.4103\/idoj.IDOJ_226_19.","DOI":"10.4103\/idoj.IDOJ_226_19"},{"key":"2025121209012902091_j_jcim-2021-0057_ref_041","doi-asserted-by":"crossref","unstructured":"Ali, M, Chaudhary, N. Ficus hispida Linn.: a review of its pharmacognostic and ethnomedicinal properties. Pharmacogn Rev 2011;5:96\u2013102. https:\/\/doi.org\/10.4103\/0973-7847.79104.","DOI":"10.4103\/0973-7847.79104"},{"key":"2025121209012902091_j_jcim-2021-0057_ref_042","doi-asserted-by":"crossref","unstructured":"Mahboubi, M. Zingiber officinale Rosc. essential oil, a review on its composition and bioactivity. Clin Phytoscience 2019;5:1\u201312. https:\/\/doi.org\/10.1186\/s40816-018-0097-4.","DOI":"10.1186\/s40816-018-0097-4"}],"container-title":["Journal of Complementary and Integrative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2021-0057\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2021-0057\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T11:25:02Z","timestamp":1765538702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2021-0057\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,6,3]]},"published-print":{"date-parts":[[2023,3,14]]}},"alternative-id":["10.1515\/jcim-2021-0057"],"URL":"https:\/\/doi.org\/10.1515\/jcim-2021-0057","relation":{},"ISSN":["1553-3840"],"issn-type":[{"value":"1553-3840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,23]]}}}